Branaplam

Branaplam (LMI070, NVS-101) is an experimental compound being developed by Novartis as a treatment for SMA. It is a small-molecule drug which modifies alternative splicing of the SMN2 gene, bringing about increased levels of SMN protein. Branaplam is taken orally, usually in a liquid form once a week.

Clinical trials

Since late 2015, branaplam has been undergoing a clinical trial in SMA type 1 children. The trial was opened in Belgium, Denmark, Germany, and Italy and recruited 13 babies aged up to 7 months. In May 2016, severe adverse effects were observed in animals being fed the drug and Novartis decided to reduce the dose 10-fold. Following this, most children rapidly deteriorated and two passed away. The target dose was restored in July 2016 upon demands of clinicians conducting the study. However, it then closed for recruitment of new patients for over a year.

The trial re-opened for recruitment in September 2017 with several new sites added to the programme across eastern Europe. Recruitment closed in March 2019.

The company communicated that it intends to test branaplam also in other SMA types.

More information

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more